Degarelix vs Leuprolide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicDegarelixLeuprolide
What it is

A GnRH receptor antagonist: the label states that it binds reversibly to pituitary GnRH receptors, reducing release of the hormones that drive testosterone production.1

A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.3

FDA status

FDA-approved

FDA-approved as Firmagon for advanced prostate cancer1,2

FDA-approved. Drugs@FDA lists Firmagon with an original approval date of December 24, 2008. The cited label has no boxed warning.1,2

Is degarelix FDA-approved?

FDA-approved

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products3,4,5,6,7,8

FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.3,4,6

Is leuprolide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial NCT00295750: an open-label, multicenter, randomized trial in 610 participants, men with prostate cancer, comparing degarelix with leuprolide for one year, described in the label as the trial that evaluated its safety and efficacy.1

Limited human data

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.3
Records collected

30 ClinicalTrials.gov records and 31 PubMed records collected

117 ClinicalTrials.gov records and 48 PubMed records collected

Area of study

Cancer1

Sexual and reproductive health, Cancer

Latest dated events
  1. DailyMed publishes the Firmagon label version cited on this page.1
  2. FDA approves Firmagon, according to Drugs@FDA.2
  1. FDA approves Vobrig for central precocious puberty in children.7,8
  2. DailyMed publishes the Eligard label version cited on this page.3
  3. FDA approves Fensolvi, according to Drugs@FDA.10

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FIRMAGON (degarelix) kit · SPL version 18 · published 2024-02-01 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: FIRMAGON (degarelix acetate), NDA 022201 · original approval December 24, 2008 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026